Reata Pharmaceuticals Announces Participation in The Goldman Sachs 42nd Annual Global Healthcare Conference
07 juin 2021 13h30 HE
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, June 07, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that...
Reata Announces that The FDA Has Asked The Company to Request a Pre-NDA Meeting for Omaveloxolone for the Treatment of Friedreich’s Ataxia
19 mai 2021 06h45 HE
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, May 19, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it...
Reata Pharmaceuticals, Inc. Announces First Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs
06 mai 2021 06h45 HE
|
Reata Pharmaceuticals, Inc.
ANNOUNCES FDA ACCEPTED FOR FILING REATA’S NDA OF BARDOXOLONE FOR THE TREATMENT OF PATIENTS WITH CKD CAUSED BY ALPORT SYNDROME IF APPROVED, BARDOXOLONE MAY BECOME THE FIRST APPROVED THERAPY FOR ALPORT...
Reata Pharmaceuticals Announces Presentations at Upcoming Investor Conferences
03 mai 2021 06h45 HE
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, May 03, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that...
Reata Pharmaceuticals, Inc. To Report First Quarter 2021 Financials and To Provide an Update on Development Programs on May 6, 2021
28 avr. 2021 17h00 HE
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, April 28, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it will...
Reata Announces FDA Accepted for Filing the NDA for Bardoxolone for the Treatment of Patients With Chronic Kidney Disease Caused by Alport Syndrome
26 avr. 2021 16h54 HE
|
Reata Pharmaceuticals, Inc.
Approximately 30,000-60,000 Patients in the United States Are Affected With Alport Syndrome, a Life-Threatening Disease With No Approved Therapies Application Assigned a PDUFA Date of February 25,...
Reata Announces the Appointments of Christy J. Oliger and Shamim Ruff to Its Board of Directors
15 avr. 2021 06h45 HE
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, April 15, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the...
Reata Pharmaceuticals Announces Presentations at Upcoming Medical Conferences
29 mars 2021 17h34 HE
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, March 29, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that...
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results and Provides an Update on Clinical Development Programs
01 mars 2021 06h35 HE
|
Reata Pharmaceuticals, Inc.
ANNOUNCES FIRST NDA SUBMISSION FOR COMPANY’S LEAD PROGRAM: BARDOXOLONE IN ALPORT SYNDROME PROVIDES UPDATE ON FALCON STUDY OF BARDOXOLONE IN ADPKD ANNOUNCES FIRST PATIENT ENROLLED IN MERLIN TRIAL...
Reata Pharmaceuticals, Inc. Submits NDA for Company’s Lead Program: Bardoxolone in Alport Syndrome
01 mars 2021 06h30 HE
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, March 01, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it has...